Рассеянный склероз: современная концепция патогенеза и патогенетического лечения

Обложка


Цитировать

Полный текст

Аннотация

Концепция патогенеза рассеянного склероза в настоящее время включает выделение начальной воспалительной фазы, сопровождающейся фазой демиелинизации, а затем фазой нейродегенерации. В статье рассматриваются механизмы иммуновоспалительных реакций и аксонального повреждения при рассеянном склерозе. Определяющая роль иммунной системы в патогенезе заболевания определяет терапевтические подходы. Иммунологические эффекты глюкокортикостероидов обусловливают их положительное влияние при обострении болезни. Для длительной терапии, модулирующей течение рассеянного склероза, широко используются две группы препаратов (интерфероны бета и глатирамера ацетат). Назначение цитостатических препаратов и иммуноглобулинов при данном заболевании также определяется их иммуномодулирующими эффектами. Обсуждаются перспективы патогенетической терапии рассеянного склероза.

Об авторах

И. A. Завалишин

ФГБНУ «Научный центр неврологии»

Email: a.v.pesedova@mail.ru
Россия, Москва

A. В. Переседова

ФГБНУ «Научный центр неврологии»

Автор, ответственный за переписку.
Email: a.v.pesedova@mail.ru
Россия, Москва

Список литературы

  1. Бархатова В.П., Завалишин И.А., Хайдаров Б.Т. Нейротрансмиттеры в механизмах связи между нервной и иммунной системами при рассеянном склерозе. Журн. невролог. и психиатрии им. С.С.Корсакова 1998; 11: 51–54.
  2. Гусев Е.И., Демина Т.Л., Бойко А.Н. Рассеянный склероз. М.: Нефть и газ, 1997. 463 с.
  3. Завалишин И.А., Захарова М.Н. Рассеянный склероз: основные аспекты патогенеза. В кн.: Гусев Е.И., Завалишин И.А., Бойко А.Н. (ред.) Рассеянный склероз и другие демиелинизирующие заболевания. М.: Миклош, 2004: 60–74.
  4. Aharoni R., Arnon R., Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neurosci. 2005; 25: 8217–8228.
  5. Aharoni R., Kayhan B., Eilam R. et al. Glatiramer acetate specific T-cells in the brain express T-helper 2/3 cytokines and brain derived neurotrophic factor in situ. Proc. Natl. Acad. Sci. USA. 2003; 100: 14157–14162.
  6. Araque A., Parpura V., Sanzgiri R.P., Haydon P.G. Tripartite synapses: glia, the unacknowledged partner. Trends. Neurosci. 1999; 22: 208–215.
  7. Bielekova B., Goodwin B., Richert N. et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83399) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000; 6: 1167–1175.
  8. Biernacki K., Antel J.P., Blain M. et al. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch. Neurol. 2005; 62: 563–568.
  9. Boutros T., Croze E., Yong V.W. Interferon b is a potent promoter of nerve growth factor production by astrocytes. J. Neurochem. 1997; 69: 939–946.
  10. Brown KA. Factors modifying the migration of lymphocytes across the blood brain barrier. Int. Immunopharmacol. 2001; 1: 2043–2062.
  11. Clanet M., Montalban X. (chairmen). The future of multiple sclerosis therapies. PAREXEL MMS Europe Ltd. 2006: 51 p.
  12. Compston A. Mechanisms of axon-glial injury of the optic nerve. Eye 2004; 18: 1182–1187.
  13. Compston A., Coles A. Multiple sclerosis. Lancet 2002; 359: 1221–1231.
  14. Cuzner M.L. Molecular biology of microglia. In: Russel W.C. (ed.) Molecular biology of multiple sclerosis. England: John Wiley & Sons Ltd., 1997: 97–120.
  15. Dong C., Flavell R.A. Cell fate decision: T-helper 1 and 2 subsets in immune responses. Arthritis Res. 2000; 2: 179–188.
  16. Ebers G., Traboulsee A., Li D. et al. Final results from the interferon betaa1b 166year longgterm follow up study. Mult. Scler. 2006; 12, Suppl. 1: S. 189 (P666).
  17. European Study Group on Interferon betaa1b in Secondary Progressive MS. Placeboocontrolled multicenter randomized trial of interferon bb1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–1497.
  18. Felts P.A. The role of ion channel distribution, dysfunction and gene expression in demyelinating disease. In: Rose M., Griggs R. (eds.) Channelopathies of the nervous system. Bodmin: MPG Books Ltd., 2001: 125–137.
  19. Filippi M., Bozzali M., Rovaris M. et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126: 433–437.
  20. Filippi M., Rovaris M., Rocca M.M. et al. European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology 2001; 57: 731–733.
  21. Ford C.C., Johnson K.P., Lisak R.P. et al. A prospective open label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult. Scler. 2006; 12: 309–320.
  22. Fossier P., Blanchard B., Ducrocq C. et al. Nitric oxide transforms serotonin into an active form and this affects neuromodulation. Neuroscience 1999; 93: 597–603.
  23. Gold R., Buttgereit F., Toyka K.V. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J. Neuroimmunol. 2001; 117: 1–8.
  24. Gonsette R.E. Combination therapy for multiple sclerosis. Int. MS J. 2004; 11: 10–21.
  25. Hemmer B., Archelos J.J., Hartung H..P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 2002; 3: 291–301.
  26. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives [Invited review]. Brain 1997; 120: 865–916.
  27. Hohlfeld R., Kerchensteiner M., Stadelmann C. et al. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J. Neuroimmunol. 2000; 107: 161–166.
  28. Hohlfeld R., Wekerle H. Drug insight: using monoclonal antibodies to treat multiple sclerosis. Nat. Clin. Pract. Neurol. 2005; 1: 34–44.
  29. Jacobs L.D., Cookfair D.L., Rudick R.A. et al. Intramuscular interferon betaa1a for disease progression in exacerbating remitting mulltiple sclerosis. Ann. Neurol. 1996; 39: 285–294.
  30. Johnson K.P., Brooks B.R., Cohen J.A. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double blind, placebo-controlled trial. Neurology 1995; 45: 1268–1276.
  31. Johnson K.P., Calabresi P.A. Interferonnbb1b: prophylactic therapy in multiple sclerosis. In: Cook S.D. (ed.) Handbook of multiple sclerosis. 3d ed. Marcel Dekker Inc., 2001: 503–518.
  32. Kappos L., Traboulsee A., Constantinescu C. et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing remitting MS. Neurology 2006; 67: 930–931. 33. Kara P., Freidlander M.J. Dynamic modulation of cerebral cortex synaptic function by nitric oxide. Prog. Brain Res. 1998; 118: 183–198.
  33. Kerschensteiner M., Stadelmann C., Dechant G. et al. Neurotrofic cross talk between the nervous and immune systems: implications for neurological diseases. Ann. Neurol. 2003; 53: 292–304.
  34. Kornek B., Storch M., Bauer J. et al. Distribution of calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 2001; 124: 1114–1124.
  35. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 2000; 6: 1399–1402.
  36. Lassmann H., Bruck W., Lucchinett C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 2001; 7: 115–121.
  37. LoPachin R., Lehning E. Mechanisms of calcium entry during axon injury and degeneration. Toxicol. Appl. Pharmacol. 1997; 143: 233–244.
  38. Lucchinetti C., Bruck W., Parisi J. et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000; 47: 707–717.
  39. Miller D.H., Khan O.A., Sheremata W.A. et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2003; 348: 15–23.
  40. Morrissey S.P., Le Page E., Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int. MS J. 2005; 12: 74–87.
  41. Neuhaus O., Archelos J.J., Hartung H..P. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. TRENDS Pharmacol. Sci. 2003; 24: 131–138.
  42. Neuhaus O., Farina C., Wekerle H., Hohlfeld R. Mechanism of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56: 702–708.
  43. Neuhaus O., Strasser-Fuchs S., Fazekas F. et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 2002; 59: 990–997.
  44. Neuhaus O., Wiendl H., Kieseier B.C. et al. Multiple sclerosis: mitoxantrone promoted differential effects on immunocompetent cells in vitro. J. Neuroimmunol. 2005; 168: 128–137.
  45. Neumann H., Cavalie A., Jenne D., Wekerle H. Induction of MHC class I genes in neurons. Science 1995; 269: 549–552.
  46. Panitch H. Prophylactic therapy – glatiramer acetate (Copaxone). In: Cook S.D. (ed.) Handbook of multiple sclerosis. 3d ed. Marcel Dekker Inc., 2001: 541–560.
  47. Paz Soldan M.M., Rodriguez M. Heterogeneity of pathogenesis in multiple sclerosis: implications for promotion of remyelination. The Journal of infections diseases 2002; 186, Suppl. 2: S. 248–253.
  48. Perumal J., Filippi M., Ford C. Glatiramer acetate therapy for multiple sclerosis: a review. Expert. Opin. Drug. Metab. Toxicol. 2006; 2: 1019–1029.
  49. Polman C., Barkhof F., Kappos L. et al. Oral interferon betaa1a in relapsing remitting multiple sclerosis: a double blind randomised study. Mult. Scler. 2003; 9: 342–348.
  50. PRISMS Study Group. Randomized double blind placebo-controlled study of interferon bb1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498–1504.
  51. Rieckmann P., Maurer M. Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis. Curr. Opin. Neurol. 2002; 15: 361–370.
  52. Sawcer S., Maranian M., Setakis E. et al. A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. Brain 2002; 125: 1337–1347.
  53. Serono International S.A. The pathophysiology of MS and mode of action of interferon beta. DVDDvideo. 2004.
  54. SPECTRIMS Study Group. Randomized controlled trial of interferon- beta 1a in secondary progressive MS. Clinical results. Neurology 2001; 56: 1496–1504.
  55. Steinman L. Multiple sclerosis: a two stage disease. Natl. Immunol. 2001; 2: 762–764.
  56. The IFNB Multiple Sclerosis Study Group. Interferon beta 1b is effective in relapsing remitting multiple sclerosis: I. Clinical results of a multicentral, randomized double-bind, placebo-controlled trial. Neurology 1993; 43: 655–661.
  57. Trapp B.D., Ransohoff R.M., Fisher E., Rudick R.A. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999; 5: 48–57.
  58. Venken K., Hellings N., Hensen K. et al. Secondary progressive in contrast to relapsing remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory TTcell function and FOXP3 expression. J. Neurosci. Res. 2006; 83: 1432–1446.
  59. Villoslada P., Hauser S.L., Bartke I. et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J. Exp. Med. 2000; 191: 1799–1806.
  60. Wang S., Cheng Q., Malik S., Yang J. Interleukin-1beta inhibits gammaaaminobutyric acid type A (GABA (A)) receptor current in cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 2000; 292: 497–504.
  61. Weitz Schmidt G., Welzenbach K., Brinkmann V. et al. Statins selectively inhibit leukocyte function antigen 1 by binding to a novel regulatory integrin site. Nat. Med. 2001; 7: 687–692.
  62. Wiles C.M., Brown P., Chapel H. et al. Intravenous immunoglobulin in neurological disease: a specialist review. J. Neurol. Neurosurg. Psychiatry 2002; 72: 440–448.
  63. Yong V.W. Differential mechanisms of action of interferonnb and glatiramer acetate in MS. Neurology 2002; 59: 802–808.
  64. Yong V.W., Chabot S., Stuve O., Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51: 682–689.
  65. Ziemssen T., Kumpfel T., Klinkert W.E. et al. Glatiramer acetatee specific T-helper 11 and 22 type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain derived neurotrophic factor. Brain 2002; 125: 2381–2391.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Zavalishin I.A., Peresedova А.V., 2007

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах